FREE TREATMENT REPORT

See ratings and reviews when you sign up for an account.

Leukocyte Migration and Differentiation in COPD Patients Compared to Healthy Smokers and Healthy Non-Smoking Subjects.

This study is currently Recruiting

September 2006 By Imperial College London

First Recieved on September 6, 2005

Last Updated on September 6, 2006

Sponsor: Imperial College London
Collaborators:
Information provided by: Imperial College London
Identifier: NCT00147082

Purpose

The aim of this study is to investigate the mechanisms whereby leukocytes are recruited to the lung in chronic obstructive pulmonary disease (COPD) and cause tissue destruction. The hypothesis is that in COPD more leukocytes enter the lung and it is these cells that are responsible for the degradation of lung tissue. We, the researchers at Imperial College London, will isolate leukocytes from the blood of patients with COPD, healthy smokers and normal subjects and measure the movement of the leukocytes to chemoattractants. We will examine further, which cell surface receptors are responsible for this trafficking of cells. Furthermore, the differentiation of these cells in vitro will be compared with cells from healthy smokers and normal subjects. Specifically, the expression of enzymes that are responsible for tissue destruction and the cell surface receptors on these cells will be investigated. The objective is to identify the mechanisms whereby leukocytes from COPD patients behave differently to cells from healthy smokers and normal subjects with a view to identify novel targets for drug therapy.

Study Type: Observational
Study Design: Observational Model: Defined Population, Observational Model: Natural History, Time Perspective: Cross-Sectional, Time Perspective: Retrospective/Prospective

Eligibility

Ages Eligible for Study:21 Years
Genders Eligible for Study:Both
Accepts Healthy Volunteers:Accepts Healthy Volunteers
Criteria

Inclusion Criteria: - Healthy Non-Smoking Subjects. All normal volunteers will meet the following criteria: - Age 21-70 years. - No history of respiratory or allergic disease. - Normal baseline spirometry as predicted for age, sex and height. - Non-smokers. - No history of upper respiratory tract infection in the preceding six weeks. - Not taking regular medication - COPD Subjects. COPD is diagnosed according to American Thoracic Society, European Respiratory Society and British Thoracic Society guidelines. All COPD volunteers will meet the following criteria: - Age between 40-75 years. - A smoking history of at least 20 pack years. (1 pack year = 20 packs of cigarettes per day for 1 year) - Forced expiratory volume at 1 second : Forced vital capacity (FEV1:FVC) ratio of <0.7, post-bronchodilator FEV1 of <85% predicted, reversibility with inhaled beta2-agonist of <15% of predicted FEV1: all three criteria are required. - Current smokers or smokers who had ceased smoking for at least 6 months. - No history of exacerbation, oral steroid or antibiotic use within the preceding 6 weeks. - Normal serum alpha-1 antitrypsin level. - No history of other respiratory or allergic disease. - No evidence of atopy on skin prick testing to common aeroallergens (grass pollen, cat hair, house dust mite or Aspergillus fumigatus - Healthy Smokers. All healthy smoking volunteers in trials will meet the following criteria: - Age 21-70 years. - Smoking history of at least 10 pack years. (1 pack year = 10 packs of cigarettes per day for 1 year). - No history of respiratory or allergic disease. - Normal baseline spirometry as predicted for age, sex and height. - No history of upper respiratory tract infection in the preceding six weeks. - Not taking regular medication. Exclusion Criteria: Subjects will not be included in this study if they meet any of the following exclusion criteria: - Clinically significant findings in the medical history or on physical examination other than those of COPD in the COPD group. - Pregnant women or mothers who are breastfeeding. - Subjects who are unable to give informed consent.

Investigators

  • Investigator: Louise E Donnelly, PhD - Principal Investigator - Imperial College London

Locations

  • Royal Brompton Hospital/NHLI Imperial College London

    London, SW3 6LY United Kingdom

advertisement
V2012.311.925.327
Disclaimer: The list and ratings above are for informational purposes only, and is intended to supplement, not substitute for, the expertise and judgment of your physician, pharmacist or other healthcare professional. The goal of the information is to provide you with a comprehensive view of all available treatments, but should not be construed to indicate that use of any one treatment is safe, appropriate, or effective for you. Decisions about use of a new treatment, or about a change in your current treatment plan, should be in consultation with your doctor or other healthcare professional.